Dr. Xiaojing Xing 邢晓静
Chief Physician
Breast Surgery (II), Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, biological therapy, and integrated traditional Chinese and Western medicine for malignant lymphoma, multiple myeloma, breast cancer, lung cancer, and digestive tract tumors. Provides symptomatic supportive care for patients with advanced cancer.
Dr. Xing is Chief of the Hematology and Breast Internal Medicine Department, holds a medical doctorate and a postdoctoral degree in traditional Chinese medicine, and serves as a master’s supervisor. An expert in the National Health Commission’s lymphoma quality control project group, Dr. Xing leads multiple national and provincial research projects and has published over 10 papers in core journals.
Professional roles
- Member, Lymphoma Group, Oncology Branch, Chinese Medical Association
- Standing Committee Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Member, Anti-Lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Multidisciplinary Team (MDT) Professional Committee, Liaoning Province
Name order: in Chinese the family name comes first (Xing Xiaojing). Papers usually list the name as Xiaojing Xing or Xing X.
Selected publications
31 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cell Mol Med, 2024 (first author): FKBP3 aggravates the malignant phenotype of diffuse large B-cell lymphoma by PARK7-mediated activation of Wnt/β-catenin signalling. PubMed 37987202
- Cancer Biol Ther, 2023 (first author): Ras interacting protein 1 facilitated proliferation and invasion of diffuse large B-cell lymphoma cells. PubMed 36967521
- Oncol Rep, 2023 (first author): Promoting effects of calponin 3 on the growth of diffuse large B‑cell lymphoma cells. PubMed 36660952
- J Cancer, 2022 (first author): LncRNA SNHG5 can Regulate the Proliferation and Migration of Diffuse Large B Cell Lymphoma Progression via Targeting miR-181-5p/XIAP. PubMed 35154447
- Mol Cell Biochem, 2018 (senior author): Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction. PubMed 29761248
- Cancer Manag Res, 2018 (senior author): A novel SWIM domain protein ZSWIM5 inhibits the malignant progression of non-small-cell lung cancer. PubMed 30233241
- Mol Med Rep, 2015 (first author): Knockdown of biglycan expression by RNA interference inhibits the proliferation and invasion of, and induces apoptosis in, the HCT116 colon cancer cell line. PubMed 26459740
- Tumour Biol, 2015 (first author): Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer. PubMed 25371074
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion